304 related articles for article (PubMed ID: 18608100)
1. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
Sakowski SA; Schuyler AD; Feldman EL
Amyotroph Lateral Scler; 2009 Apr; 10(2):63-73. PubMed ID: 18608100
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor system in amyotrophic lateral sclerosis.
Wilczak N; Keyser J
Endocr Dev; 2005; 9():160-169. PubMed ID: 15879696
[TBL] [Abstract][Full Text] [Related]
3. Neurotrophic and Neuroregenerative Effects of GH/IGF1.
Bianchi VE; Locatelli V; Rizzi L
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29149058
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
Lewis ME; Neff NT; Contreras PC; Stong DB; Oppenheim RW; Grebow PE; Vaught JL
Exp Neurol; 1993 Nov; 124(1):73-88. PubMed ID: 8282084
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Mitchell JD; Wokke JH; Borasio GD
Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
[TBL] [Abstract][Full Text] [Related]
6. [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].
Kollewe K; Dengler R; Petri S
Nervenarzt; 2008 Jun; 79(6):653-61. PubMed ID: 18210046
[TBL] [Abstract][Full Text] [Related]
7. Strategic approaches to developing drug treatments for ALS.
Vincent AM; Sakowski SA; Schuyler A; Feldman EL
Drug Discov Today; 2008 Jan; 13(1-2):67-72. PubMed ID: 18190866
[TBL] [Abstract][Full Text] [Related]
8. Additivity and potentiation of IGF-I and GDNF in the complete rescue of postnatal motor neurons.
Bilak MM; Corse AM; Kuncl RW
Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Jun; 2(2):83-91. PubMed ID: 11675876
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
Borasio GD; Robberecht W; Leigh PN; Emile J; Guiloff RJ; Jerusalem F; Silani V; Vos PE; Wokke JH; Dobbins T
Neurology; 1998 Aug; 51(2):583-6. PubMed ID: 9710040
[TBL] [Abstract][Full Text] [Related]
10. [Research in amyotrophic lateral sclerosis: what is new in 2009?].
Pradat PF; Attarian S; Camdessanché JP; Carluer L; Cintas P; Corcia P; Echaniz-Laguna A; Gonzalez-Bermejo J; Guy N; Nicolas G; Perez T; Soriani MH; Vandenberghe N; Verschueren A;
Rev Neurol (Paris); 2010; 166(8-9):683-98. PubMed ID: 20472259
[TBL] [Abstract][Full Text] [Related]
11. Autocrine production of IGF-I increases stem cell-mediated neuroprotection.
Lunn JS; Sakowski SA; McGinley LM; Pacut C; Hazel TG; Johe K; Feldman EL
Stem Cells; 2015 May; 33(5):1480-9. PubMed ID: 25532472
[TBL] [Abstract][Full Text] [Related]
12. Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity.
Saenger S; Holtmann B; Nilges MR; Schroeder S; Hoeflich A; Kletzl H; Spooren W; Ostrowitzki S; Hanania T; Sendtner M; Metzger F
Amyotroph Lateral Scler; 2012 Sep; 13(5):418-29. PubMed ID: 22871074
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.
Nagano I; Ilieva H; Shiote M; Murakami T; Yokoyama M; Shoji M; Abe K
J Neurol Sci; 2005 Aug; 235(1-2):61-8. PubMed ID: 15990113
[TBL] [Abstract][Full Text] [Related]
14. The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features.
Pellecchia MT; Pivonello R; Monsurrò MR; Trojsi F; Longo K; Piccirillo G; Pivonello C; Rocco M; Di Somma C; Colao A; Tedeschi G; Barone P
Eur J Neurol; 2010 May; 17(5):666-71. PubMed ID: 20002733
[TBL] [Abstract][Full Text] [Related]
15. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
Cheah BC; Vucic S; Krishnan AV; Kiernan MC
Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis.
Rauskolb S; Dombert B; Sendtner M
Neurobiol Dis; 2017 Jan; 97(Pt B):103-113. PubMed ID: 27142684
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies.
Festoff BW; Yang SX; Vaught J; Bryan C; Ma JY
J Neurol Sci; 1995 May; 129 Suppl():114-21. PubMed ID: 7595601
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Mitchell JD; Wokke JH; Borasio GD
Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
[TBL] [Abstract][Full Text] [Related]
19. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
Yanagisawa N; Shindo M
Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
[TBL] [Abstract][Full Text] [Related]
20. Gene and protein therapies utilizing VEGF for ALS.
Keifer OP; O'Connor DM; Boulis NM
Pharmacol Ther; 2014 Mar; 141(3):261-71. PubMed ID: 24177067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
